Drugs: Marketing

Department of Health and Social Care written question – answered on 26th June 2018.

Alert me about debates like this

Photo of Lord Hunt of Kings Heath Lord Hunt of Kings Heath Labour

To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 June (HL8120), whether they will publish the information the European Commission has provided on how SecurMed’s fee model compares with other European Union National Medicines Verification Organisations.

Photo of Lord O'Shaughnessy Lord O'Shaughnessy The Parliamentary Under-Secretary for Health and Social Care

SecurMed’s fee model is based on a template (blue print) developed by stakeholders at a European level and published by the European Medicines Verification Organisation (EMVO). We know from discussions at the Commission led European Union Expert Group meetings that the flat fee model is being used by other National Medicines Verification Organisations (NMVOs) across Europe and therefore the United Kingdom is in line with other EU countries. It is for the EMVO and NMVOs to publish further information, rather than for the Department or the Medicines and Healthcare products Regulatory Agency in their supervisory role.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.